about
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Scientific and Regulatory Policy Committee (SRPC) Review: Interpretation and Use of Cell Proliferation Data in Cancer Risk Assessment.Tumor tissue protein signatures reflect histological grade of breast cancerLimitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling indexKi67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesAnalytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital imagesEvaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarraysPathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional studyMitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma.Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial.Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.Digital immunohistochemistry platform for the staining variation monitoring based on integration of image and statistical analyses with laboratory information systemMarkers for the identification of late breast cancer recurrence.Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyAn interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.Development and verification of the PAM50-based Prosigna breast cancer gene signature assayDifferences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study.A Comparison of Visual Assessment and Automated Digital Image Analysis of Ki67 Labeling Index in Breast Cancer.Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast CancersCorrelation Between Clinical-Pathologic Factors and Long-Term Follow-Up in Young Breast Cancer PatientsTechnical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole.Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort studyPrognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St. Gallen consensus classification.A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method
P2860
Q27304609-F48544A5-DCCB-48AB-9B8A-C4BC86F25234Q27853207-397E3921-1F71-45CB-88E4-679641BA7B37Q28069856-12FF19FE-139D-439A-9FC7-1CB445234D59Q28079118-55B38966-3DA5-4F3E-9F18-2B13ABF6759CQ28084216-C93736EF-5330-44AF-8D37-2880E7C71F68Q28085062-662D3E07-528D-4306-AC9C-A6DEEA678B11Q30938639-49007F63-60B2-4F3E-BAE7-22E26FDEE54CQ33365644-3A8AC0D4-63C0-45AC-A5C9-0AA460ACEC5DQ33591751-854ECA89-902F-46DF-AECA-2692758D6648Q33660598-11EA2086-297F-461C-A013-3D11C413D499Q33688564-B1603FAD-4EE9-4FF3-BDCC-DFAE5BF7F151Q33717341-9AFB3AA9-BB24-43AA-B144-AE04A6377895Q33843751-A07ED84B-0BDE-4623-ADDD-25CDD78A7439Q33867326-18B5E749-0729-4294-ACB0-E4DEA4265908Q33892778-DD79672A-2DFF-426B-A38A-91B06A73867AQ33915010-17E894C2-410F-4F17-86D4-84B1FF2C06CBQ33915270-CA55DD2D-50C2-4010-8D16-173D6BB2BB93Q34466187-2278BAC1-7443-42DA-B954-DD7A1BB2233EQ34567461-6E71F435-D2B8-4021-BF56-51BD9BA209ECQ34980413-A07612C3-BC69-495E-BFEA-15A254731530Q35000609-350F36FD-F471-41CF-ABA8-0940DC0C4C4FQ35000713-AEA85689-30D3-4803-8A15-0F5EDA28B3D9Q35011466-CF619E1D-FCDD-4D3E-9E98-BEE97FD51008Q35018949-C8E632D0-249C-46CC-B284-160461E4AA1DQ35160045-6B76B324-1A9B-4B1F-A5E3-56AD4B8883C5Q35186057-8A604F34-A862-49F5-ABA4-4C5A5BD45279Q35347732-4D9598EE-13B2-4600-9DB6-30D155E40DC6Q35462377-269AD00F-5C25-4417-A0C3-F417F91829FEQ35560945-6207A747-8A60-4A8A-B5B4-424C70B8431AQ35752868-2BB98CE7-852A-492A-B995-27234A90FA38Q35813033-0901F805-D4DF-487A-8DCB-6418C23AA856Q35909626-17182534-0E8F-4E30-96CF-7D7C5D9CBEA7Q35940233-0CD491A3-4EA5-4732-9216-C2E6E4BE04F3Q35949292-F8A5DE80-7285-4D10-8C7E-2B53BABCBCA7Q36038013-D17297FB-1B58-4419-8E95-834B3D2BBB77Q36070547-0EFC0CC0-27E2-4BD1-A23C-3423D9ED1A21Q36081380-8304CB3F-1B88-4132-AB74-7329E29F0D2AQ36135274-A778A891-C23E-4503-A89F-DB75921ED607Q36243382-CB8B16D4-D0D4-4D96-AF14-47AB32B4A21FQ36277052-9F4C112C-FC94-4F15-852A-72AF32DBFE46
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
An international Ki67 reproducibility study.
@en
An international Ki67 reproducibility study.
@nl
type
label
An international Ki67 reproducibility study.
@en
An international Ki67 reproducibility study.
@nl
prefLabel
An international Ki67 reproducibility study.
@en
An international Ki67 reproducibility study.
@nl
P2093
P2860
P50
P356
P1476
An international Ki67 reproducibility study.
@en
P2093
Allen M Gown
Daniel F Hayes
Dongxia Gao
Erika Mehl
International Ki67 in Breast C ...... h American Breast Cancer Group
John M S Bartlett
Judith C Hugh
Lila A Zabaglo
Lisa M McShane
Mauro G Mastropasqua
P2860
P304
P356
10.1093/JNCI/DJT306
P407
P577
2013-11-07T00:00:00Z